MARKET

IMRX

IMRX

Immuneering Corp
NASDAQ
6.69
-0.05
-0.74%
Closed 19:32 12/04 EST
OPEN
6.76
PREV CLOSE
6.74
HIGH
6.81
LOW
6.60
VOLUME
589.60K
TURNOVER
0
52 WEEK HIGH
10.08
52 WEEK LOW
1.100
MARKET CAP
431.97M
P/E (TTM)
-3.7521
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMRX last week (1124-1128)?
Weekly Report · 4d ago
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 11/26 17:00
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High?
NASDAQ · 11/26 14:55
Immuneering Corporation to Present at Piper Sandler Annual Healthcare Conference
Reuters · 11/25 13:00
Weekly Report: what happened at IMRX last week (1117-1121)?
Weekly Report · 11/24 09:26
U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels
Reuters · 11/24 08:05
Immuneering Showcases Promising Phase 2 Pancreatic Cancer Data for Atebimetinib Combination
Reuters · 11/21 21:33
Immuneering (IMRX) Gets a Buy from Mizuho Securities
TipRanks · 11/18 08:16
More
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Webull offers Immuneering Corp stock information, including NASDAQ: IMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMRX stock methods without spending real money on the virtual paper trading platform.